Current Issue

View Larger Image

Past Issues Adlink Subscription Visit Our Publisher

ADVERTISEMENT



Top Keywords




Roche

click to enlarge

Immunoassay Module

The cobas® e 602 analyzer represents the latest addition to the cobas 8000 modular analyzer series for diagnostic labs with high-volume workloads. Labs can now combine this new immunoassay module with two existing clinical chemistry modules to create an integrated platform with 24 unique system configurations to match their specific testing needs. The cobas e 602 module uses electrochemiluminescence technology and includes more than 50 assays on its initial test menu. It offers a throughput of up to 170 immunoassay tests per hour, and when combined with the existing clinical chemistry modules (cobas c 701, cobas c 502), 10 unique configurations are available that offer a throughput of 3,670 to 7,970 tests per hour. The cobas e 602 module is also available in four immunoassay-only configurations, which offer a throughput of 170 to 680 tests per hour.

  • Roche
  • Sandhofer Strassse 116
  • Mannheim, 68305
  • GERMANY

Related To This Company

Products

Related content

Subscription center

GEN MAGAZINE

Genetic Engineering & Biotechnology News (GEN) has retained its position as the most widely read biotechnology publication around the globe since its launch in 1981. Published 21 times a year and with additional exclusive editorial content online, GEN's unique news and technology focus includes the entire bioproduct life cycle from early-stage R&D, to applied research including omics, biomarkers, as well as diagnostics, to bioprocessing and commercialization.

Subscribe
e-NEWSLETTERS

Add GEN to your Inbox! Subscribe today to our complimentary e-newsletters and stay abreast of the latest biotech news and trends. Click the magnifying glass icon next to a newsletter title to view a sample.

 

All fields are required

Email
Confirm Email
First Name
Last Name
Organization
E-Alert Format
 
 
  Sign Up

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

GENpoll

Funding Early-Stage Companies

How much do you think newly established funds will succeed in helping startups?

Suggest a Poll